Abel Hall LLC Sells 672 Shares of GSK plc (NYSE:GSK)

Abel Hall LLC reduced its position in GSK plc (NYSE:GSK) by 5.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 12,773 shares of the pharmaceutical company’s stock after selling 672 shares during the period. Abel Hall LLC’s holdings in GSK were worth $432,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GSK. Eastern Bank bought a new position in shares of GSK in the third quarter worth $26,000. ST Germain D J Co. Inc. boosted its stake in GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 522 shares during the period. Sunbelt Securities Inc. boosted its stake in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Concord Wealth Partners grew its holdings in GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 547 shares in the last quarter. Finally, Fortitude Family Office LLC bought a new stake in shares of GSK during the third quarter valued at about $42,000. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on GSK. StockNews.com cut shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and decreased their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Six investment analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, GSK presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Price Performance

Shares of NYSE:GSK opened at $35.06 on Thursday. The company’s fifty day moving average price is $33.98 and its 200-day moving average price is $37.75. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The firm has a market capitalization of $72.67 billion, a price-to-earnings ratio of 22.77, a PEG ratio of 1.31 and a beta of 0.63. GSK plc has a one year low of $31.72 and a one year high of $45.92.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.